[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6145 followers
Created: 2025-07-25 08:11:01 UTC

Cipla’s Growth Trajectory: Strong Margins, U.S. Biosim Launch & Market Leadership 🚀 | MCap 1,20,944.59 Cr

- Revenue growth: Income from Operations at INR XXXXX Cr (+4% YoY); One-India Business crosses INR XXXXX Cr quarterly revenue for the first time (+6% YoY).
- Profitability: EBITDA at INR XXXXX Cr (25.6% margin, +4% YoY); PAT at INR XXXXX Cr (18.7% margin, +10% YoY).
- U.S. market: North America revenue at $XXX Mn; Albuterol leads with XXXX% market share; biosimilar launch planned for Q2 FY26.
- Global expansion: Africa grows XX% YoY (USD); Emerging Markets & Europe up X% YoY (USD).
- R&D focus: INR XXX Cr invested (6.2% of sales), targeting filings and pipeline development.
- Financial strength: Net cash position of INR XXXXXX Cr; minimal debt (INR XXX Cr).
- Market leadership: Trade Generics launches X new products; Consumer Health brands (Nicotex, Omnigel) retain top spots.
- Balance sheet: Equity at INR XXXXXX Cr; Cash & Equivalents at INR XXXXXX Cr.

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of X pages)

![](https://pbs.twimg.com/media/GwsFRSibgAATY0B.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948657225964421167/c:line.svg)

**Related Topics**
[indian rupee](/topic/indian-rupee)
[quarterly earnings](/topic/quarterly-earnings)
[mcap](/topic/mcap)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1948657225964421167)